TY - JOUR
T1 - Bayesian optimal designs for a quantal dose-response study with potentially missing observations
AU - Baek, In Young
AU - Zhu, Wei
AU - Wu, Xiangfeng
AU - Wong, Weng Kee
N1 - Funding Information:
The authors wish to thank the referees for their helpful comments and Dr. Ting for his editorial comments. The work of Wong was partially supported by a grant award from the Scleroderma Foundation and NIH grant award 1R01GM072876:01A1. The research of Wu and Zhu was also supported in part by the latter award.
PY - 2006/10/1
Y1 - 2006/10/1
N2 - In a dose-response study, there are frequently multiple goals and not all planned observations are realized at the end of the study. Subjects drop out and the initial design can be quite different from the final design. Consequently, the final design can be inefficient. Single- and multiple-objective Bayesian optimal designs that account for potentially missing observations in quantal response models were recently proposed in Baek (2005). In this work, we investigate the efficiencies of the conventional optimal designs that do not incorporate potential missing information relative to our proposed designs. Furthermore, we examine the impact of restricted dose range on the resulting optimal designs. As an application, we used missing data information from a study by Yocum et al. (2003) to design a study for estimating dose levels of tacrolimus that will result in a certain percentage of rheumatoid arthritis patients having an ACR20 response at 6 months.
AB - In a dose-response study, there are frequently multiple goals and not all planned observations are realized at the end of the study. Subjects drop out and the initial design can be quite different from the final design. Consequently, the final design can be inefficient. Single- and multiple-objective Bayesian optimal designs that account for potentially missing observations in quantal response models were recently proposed in Baek (2005). In this work, we investigate the efficiencies of the conventional optimal designs that do not incorporate potential missing information relative to our proposed designs. Furthermore, we examine the impact of restricted dose range on the resulting optimal designs. As an application, we used missing data information from a study by Yocum et al. (2003) to design a study for estimating dose levels of tacrolimus that will result in a certain percentage of rheumatoid arthritis patients having an ACR20 response at 6 months.
UR - https://www.scopus.com/pages/publications/33751579944
UR - https://www.scopus.com/pages/publications/33751579944#tab=citedBy
U2 - 10.1080/10543400600860501
DO - 10.1080/10543400600860501
M3 - Article
C2 - 17037265
AN - SCOPUS:33751579944
SN - 1054-3406
VL - 16
SP - 679
EP - 693
JO - Journal of Biopharmaceutical Statistics
JF - Journal of Biopharmaceutical Statistics
IS - 5
ER -